STOCK TITAN

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Anteris Technologies Global (AVR) announced a presentation of one-year DurAVR heart-valve outcomes at PCR London Valves on November 22, 2026. Rishi Puri of Cleveland Clinic will present clinical and hemodynamic outcomes, including measures of blood flow, from a pooled cohort of 100 patients with severe aortic stenosis who received the valve.

The presentation focuses on small aortic annuli and is scheduled for the TAVI Hotline – Part 1 late-breaking session, from 9:30 AM to 10:30 AM GMT in the Dubai Room. The conference runs November 22–24 in London.

Loading...
Loading translation...

Key Figures

Cohort size: 100 patients
Cohort size
100 patients
Pooled cohort; one-year DurAVR THV outcomes are to be reported

Key Terms

tavr, aortic stenosis, thv
3 terms
tavr medical
"transcatheter aortic valve replacement (TAVR)"
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that replaces a failing aortic heart valve by delivering a new valve through a blood vessel instead of opening the chest. It matters to investors because TAVR expands who can be treated, shortens hospital stays and recovery, and shapes revenue, regulatory risk and reimbursement for medical device makers, hospitals and insurers—similar to how a popular new product can reshape an industry’s market and costs.
aortic stenosis medical
"100 patients with severe aortic stenosis"
Aortic stenosis is a narrowing of the heart’s aortic valve that makes it harder for blood to leave the heart, similar to a door that won’t open fully or a garden hose with a pinched end. It matters to investors because the condition drives demand for diagnostic tests, medicines, surgical procedures and medical devices; changes in treatment options, clinical trial results or regulatory approvals can quickly affect the revenue and valuation of companies in the healthcare and medical-device sectors.
thv medical
"DurAVR® Transcatheter Heart Valve (THV)"
A transcatheter heart valve is an artificial heart valve that doctors deliver through a thin tube inserted into a blood vessel, then expand into place to replace a damaged valve without open‑chest surgery. Think of it like fixing a leaky pipe by sliding in a new fitting instead of ripping out the whole wall; investors watch adoption rates, procedure costs, safety data and regulatory approvals because those factors drive sales, reimbursement and long‑term demand for device makers and hospitals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom.

The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR).

Session details are as follows:
Session: TAVI Hotline – Part 1
Track: Hotline / Late-Breaking Trials
Date and time: Sunday, November 22, 2026, 9:30 AM – 10:30 AM GMT/UTC+0
Location: Dubai Room
Title: One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli
Presenter: Rishi Puri, MD, PhD, Cleveland Clinic

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR® Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

For more information: 
  
Global Investor RelationsInvestor Relations (US)
investors@anteristech.commchatterjee@bplifescience.com
Debbie OrmsbyMalini Chatterjee, Ph.D.
Anteris Technologies Global Corp.Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200+1 917 330 4269
  


Websitewww.anteristech.com
X@AnterisTech
LinkedInhttps://www.linkedin.com/company/anteristech



Keep reading